Dishman Carbogen Amcis Limited reported a strong performance for Q4 FY26 and the full financial year. The company achieved a 19% revenue growth in Q4, reaching INR 851 crores, with a consolidated EBITDA of INR 163 crores. Management highlighted a healthy outlook, supported by strong performance in the CDMO and marketable molecules segments, alongside strategic plans for debt reduction through a new fundraising initiative.
Financial Highlights for Q4 and FY26
For the quarter ending 31st March, 2026, the company reported a robust revenue of INR 851 crores, marking a 19% growth compared to the same period last year. For the full financial year, income from operations stood at INR 2,932 crores, an 8% year-on-year increase. The company’s EBITDA margins for the full year improved by 200 basis points to reach 19.3%, translating to an annual EBITDA of INR 565 crores.
Segment Performance
The CDMO segment remains the primary revenue contributor, accounting for 83% of the total revenue for the full year. Despite a slight margin dip in Q4 due to high-value Phase 3 delivery cycles, this segment grew by 21% during the quarter. The marketable molecules segment, particularly Vitamin D analogs, delivered a remarkable performance with a 9.3% growth in Q4 and a 17% revenue increase for the full year, achieving a margin of 21.1% for the quarter.
Strategic Initiatives and Debt Management
Management announced a board-approved fundraising plan involving a long-term external commercial borrowing from a promoter entity. This initiative aims to repay high-cost debt in India, significantly reducing the finance cost. The company targets a net interest cost of less than INR 100 crores at a consolidated level for the next financial year. Furthermore, the company is focusing on its Sprint initiative to capture early-phase projects and leveraging its French facility to provide combined drug substance and drug product offerings, aiming for breakeven in FY28.
Future Outlook
The company maintains a positive outlook with a 15% CAGR revenue growth target over the next three years. With no major CapEx plans, the focus remains on optimizing existing assets and reducing net debt. The leadership expressed confidence in the company’s technical capabilities and the promising pipeline of ADC (Antibody-Drug Conjugate) and other late-phase innovator projects to drive future value.
Source: BSE
